Publish in this journal
Journal Information
Vol. 73. Issue 12.
Pages 1086-1087 (December 2020)
Share
Share
Download PDF
More article options
Vol. 73. Issue 12.
Pages 1086-1087 (December 2020)
Letter to the Editor
Full text access
Simultaneous percutaneous repair in mitral and tricuspid regurgitation: step by step. Response
Reparación percutánea simultánea en la insuficiencia mitral y tricuspídea: paso a paso. Respuesta
Visits
...
Rodrigo Estévez-Loureiro
Corresponding author
roiestevez@hotmail.com

Corresponding author:
, Berenice Caneiro-Queija, José Antonio Baz, Andrés Íñiguez-Romo
Servicio de Cardiología, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, Spain
Related content
Rev Esp Cardiol. 2020;73:1085-610.1016/j.rec.2020.08.017
Juan Diego Sánchez Vega, Luisa Salido Tahoces, José Luis Zamorano, Ángel Sánchez-Recalde
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
To the Editor,

First of all, we would like to thank Sánchez Vega et al. for the interest shown in our recent article. The field of combined interventional cardiology for mitral and tricuspid regurgitation (TR) is in its early stages, and the scientific evidence is still not sufficiently strong. Therefore, it is only natural that questions arise about these complex procedures. Nonetheless, some arguments support combined repair in certain cases. The presence of severe TR at the time of mitral repair has been reported to be associated with poorer prognosis, even in the short-term.1,2 Furthermore, although TR is theoretically significantly reduced after mitral repair, this outcome is seen in only 15% to 40% of patients.3 Consequently, a number of patients could experience clinical deterioration due to residual TR. Factors such as annular dilatation, degree of TR, right-sided dysfunction and dilatation, or the presence of congestive symptoms may indicate that the TR will not improve and that there is a risk of adverse events during follow-up. Once the decision has been made to treat both valves, combined treatment appears to have advantages. It is safe and feasible, it shortens the duration of the procedure compared with 2 deferred procedures, and it lowers the risks associated with a new vascular access, another hospital stay, and repeat general anesthesia in patients already at high risk. Randomized studies would be ideal, but definitive conclusions might not be reached, given the heterogeneity of the condition. In the interim, our decisions should be guided by the clinical judgment and resources of the interventional cardiology team.

References
[1]
D. Kalbacher, U. Schäfer, R.S. von Bardeleben, et al.
Impact of tricuspid valve regurgitation in surgical high-risk patients undergoing MitraClip implantation: results from the TRAMI registry.
EuroIntervention., 12 (2017), pp. e1809-e1816
[2]
Y. Ohno, G.F. Attizzani, D. Capodanno, et al.
Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry.
Eur Heart J Cardiovasc Imag., 15 (2014), pp. 1246-1255
[3]
A.H. Frangieh, C. Gruner, F. Mikulicic, et al.
Impact of percutaneous mitral valve repair using the MitraClip system on tricuspid regurgitation.
EuroIntervention., 11 (2016), pp. e1680-e1686
Copyright © 2020. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?